Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(8):630; doi:10.1093/jnci/94.8.630
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wojnowski, L.
Right arrow Articles by Brockmöller, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wojnowski, L.
Right arrow Articles by Brockmöller, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 8, 630, April 17, 2002
© 2002 Oxford University Press

CORRESPONDENCE

Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4

Leszek Wojnowski, Elisabeth Hustert, Kathrin Klein, Mark Goldammer, Michael Haberl, Julia Kirchheiner, Ina Koch, Jürgen Klattig, Ulrich Zanger, Jürgen Brockmöller

Affiliations of authors: L. Wojnowski, E. Hustert, M. Haberl, I. Koch, J. Klattig, Epidauros Biotechnologie AG; K. Klein, U. Zanger, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; J. Kirchheiner, Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany.

Correspondence to: Epidauros Biotechnologie AG, D-82347 Bernried, Germany (e-mail: info@epidauros.com).

The variable expression and activity of CYP3A isozymes observed in the population has been discussed as a factor that affects both response to therapies and the individual cancer predisposition. The CYP3A4-V gene variant in the 5`-regulatory region of the CYP3A4 gene (herein referred to as CYP3A4*1B) was associated with high-grade prostate cancer (1) and with a reduced risk for treatment-related leukemia (2). It has been postulated . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. M. Rudin, W. Liu, A. Desai, T. Karrison, X. Jiang, L. Janisch, S. Das, J. Ramirez, B. Poonkuzhali, E. Schuetz, et al.
Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
J. Clin. Oncol., March 1, 2008; 26(7): 1119 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S Leskela, E Honrado, C Montero-Conde, I Landa, A Cascon, R Leton, P Talavera, J M Cozar, A Concha, M Robledo, et al.
Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer
Endocr. Relat. Cancer, September 1, 2007; 14(3): 645 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Damaraju, D. Murray, J. Dufour, D. Carandang, S. Myrehaug, G. Fallone, C. Field, R. Greiner, J. Hanson, C. E. Cass, et al.
Association of DNA Repair and Steroid Metabolism Gene Polymorphisms with Clinical Late Toxicity in Patients Treated with Conformal Radiotherapy for Prostate Cancer
Clin. Cancer Res., April 15, 2006; 12(8): 2545 - 2554.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Zeigler-Johnson, T. Friebel, A. H. Walker, Y. Wang, E. Spangler, S. Panossian, M. Patacsil, R. Aplenc, A. J. Wein, S. B. Malkowicz, et al.
CYP3A4, CYP3A5, and CYP3A43 Genotypes and Haplotypes in the Etiology and Severity of Prostate Cancer
Cancer Res., November 15, 2004; 64(22): 8461 - 8467.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. J. Plummer, D. V. Conti, P. L. Paris, A. P. Curran, G. Casey, and J. S. Witte
CYP3A4 and CYP3A5 Genotypes, Haplotypes, and Risk of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 928 - 932.
[Abstract] [Full Text] [PDF]